1Lamb H M,Ormrod D,Scott L J,et al. Ceftriaxone, an updape of is use in the management of community-acquired and nosocomial infections [J]. Drugs, 2002,62:1 041-1 089.
4Lamb HM, Ormrod D, Scott LJ, et al. Ceftriaxone: an update of its use in the management of community-acquired and nosoeomial infections. Drugs, 2002, 62:1041-1089.
6Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet, 1988, 2: 1411-1413.
7Cochat P, Cochat N, Jouvenet M, et al . Ceftriaxone-associated nephrolithiasis . Nephro Dial Transplant, 1990, 5: 974-976.
8Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxoneassociated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterelogy, 1990, 99 : 1772-1778.
10Ozturk A, Kaya M, Zeyrek D, et al. Ultrasonographic findings in ceftriaxone: associated biliary sludge and pseudolithiasis in children. Acta Radiol, 2005, 46 : 112-116.
